2024
Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
Hoffman K, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Lee K, Kibel A, Taplin M, Kollmeier M. Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s54. DOI: 10.1016/j.ijrobp.2024.07.088.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneMonths of GnRH agonistAcetate plus prednisonePatient-reported health-related quality of lifeEPIC-26Hormonal functionHealth-related quality of lifeGnRH agonistTreatment armsTreatment to 1 yearQuality of lifeMental statusMetastasis-free survivalBaseline to endCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesRadical prostatectomyClinically meaningful differencesSaint Louis University Mental Status ExamNear baselineClinically meaningful declineT-scoreHormonal domainsIntensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boostPatient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Hoffman K, Nguyen P, Rathkopf D, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M, Kollmeier M. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP). Journal Of Clinical Oncology 2024, 42: 260-260. DOI: 10.1200/jco.2024.42.4_suppl.260.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneSaint Louis University Mental Status ExamMonths of GnRH agonistPatient-reported health-related quality of lifeEPIC-26Radical prostatectomyHealth-related quality of lifeGnRH agonistTreatment armsHormonal functionPROMIS FatigueTreatment to 1 yearQuality of lifeAcetate plus prednisoneMental statusMetastasis-free survivalBaseline to endMental status examStandardized T scoresMild neurocognitive disorderCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesClinically meaningful differences
2022
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
Runcie K, Dallos M, Khan S, Gray J, Marco P, Ping L, LaTourette D, Anderson C, Spina C, Yu J, Deutsch I, Sheeri S, Gutierrez A, Stein M. A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Journal Of Clinical Oncology 2022, 40: tps5115-tps5115. DOI: 10.1200/jco.2022.40.16_suppl.tps5115.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate-specific antigenTumor-associated antigensBiochemical recurrenceProstate cancerRadiation therapyTumor microenvironmentRadical prostatectomyStudy treatmentPromote anti-tumor immune responsesAntigen-specific T cell responsesBiochemical recurrence of prostate cancerBiochemically recurrent prostate cancerCastration sensitive prostate cancerPSA responseTime to PSA progressionDose of study treatmentAnti-tumor immune responseStandard first-line treatmentEvidence of metastatic diseaseMyeloid-derived suppressor cellsImmunosuppressive regulatory T cellsPeptide antigensLive-attenuated Listeria monocytogenesRecurrent prostate cancer
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsAssociation between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.
Yang D, Dee E, Arega M, Nguyen P, Orio P, King M, Kann B, Yu J, Cook K, Ma T, Kishan A, Muralidhar V. Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2021.39.6_suppl.205.Peer-Reviewed Original ResearchPercentage of positive biopsy coresRisk of pelvic lymph node involvementPelvic lymph node involvementLymph node involvementPositive biopsy coresPelvic lymph nodesProstate cancerRadical prostatectomyBiopsy coresNode involvementLymph nodesDefinitive treatment of prostate cancerGleason 9-10 diseasePositive pelvic lymph nodesTreatment of prostate cancerBiopsy Gleason scoreClinicopathological prognostic variablesElective nodal irradiationGleason 8 diseasePathologic nodal evaluationClinical tumor stageNational Cancer DatabaseTime of RPClinically relevant associationMultivariate logistic regression
2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient managementRadiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy
Yang DX, Verma V, An Y, Yu JB, Sprenkle PC, Leapman MS, Park HS. Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances In Radiation Oncology 2020, 5: 1225-1231. PMID: 33305083, PMCID: PMC7718530, DOI: 10.1016/j.adro.2020.08.015.Peer-Reviewed Original ResearchDefinitive radiation therapyPostoperative radiation therapyHydrogel spacerRadiation therapyRectal dosimetryProstate cancerGroup 1Rectal dose-volume parametersPostprostatectomy radiation therapyDose-volume parametersPostprostatectomy settingSurgical patientsPrimary managementRectal volumeDefinitive settingRadical prostatectomyRectal dosesGroup 2High riskPatientsLinear regression analysisProstatectomyMann-WhitneyTherapyCancerNational trends in the management of patients with positive surgical margins at radical prostatectomy
Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPositive surgical marginsUse of ADTPost-prostatectomy radiation therapyRadiation therapySurgical marginsRadical prostatectomyInitial courseNode-negative prostate cancerPost-operative radiation therapyMultivariable logistic regression modelNational Cancer DatabaseAdverse pathologic featuresManagement of patientsPost-operative managementLogistic regression modelsDeprivation therapySurgical cancersPrimary endpointRT useSecondary endpointsPathologic characteristicsPathologic featuresUninsured statusCancer DatabaseRTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
Posadas E, Gay H, Pugh S, Morgan T, Yu J, Lechpammer S, Feng F. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery. Journal Of Clinical Oncology 2020, 38: tps5601-tps5601. DOI: 10.1200/jco.2020.38.15_suppl.tps5601.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalHigh-risk featuresSalvage radiotherapyBiochemical recurrenceRadical prostatectomyProstate cancerSystemic therapyAndrogen receptorYears of androgen deprivation therapyOccurrence of biochemical failureStandard androgen deprivation therapyRandomized phase II studyIndividualization of radiotherapyNon-steroidal anti-androgenPersistently elevated PSADisease control rateRecurrent prostate cancerSeminal vesicle invasionPara-aortic nodesSuspicious lymph nodesPatient-reported toxicityRisk of progressionOne-sided alphaElevated PSA
2018
National trends in the management of patients with positive surgical margins at the time of radical prostatectomy.
Ghabili K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. National trends in the management of patients with positive surgical margins at the time of radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 111-111. DOI: 10.1200/jco.2018.36.6_suppl.111.Peer-Reviewed Original ResearchAdjuvant radiation therapyAndrogen deprivation therapyPositive surgical marginsNational Cancer DatabaseAdjuvant therapyRadical prostatectomyRadiation therapyProstate cancerPathologic featuresSurgical marginsAddition of ADTAdjuvant androgen deprivation therapyStudy periodPre-treatment PSAPrimary definitive treatmentMajority of patientsManagement of patientsGleason grade groupCourse of managementOptimal management approachNon-academic facilitiesLogistic regression modelsBinary logistic regression modelAnalysis menDeprivation therapy
2017
Increasing rate of positive margins in men with high-risk prostate cancer undergoing radical prostatectomy
Lester-Coll N, Bledsoe T, Johnson S, Nath S, Yu J. Increasing rate of positive margins in men with high-risk prostate cancer undergoing radical prostatectomy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s96. DOI: 10.1016/j.ijrobp.2017.06.231.Peer-Reviewed Original Research
2016
Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort
Wang E, Yu J, Abouassally R, Meropol N, Cooper G, Shah N, Williams S, Gonzalez C, Smaldone M, Kutikov A, Zhu H, Kim S. Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology 2016, 95: 88-94. PMID: 27318264, DOI: 10.1016/j.urology.2016.06.010.Peer-Reviewed Original ResearchConceptsHigh-risk prostate cancerWatchful waitingRadiation therapyProstate cancerPrimary treatmentTreatment of high-risk prostate cancerOdds ratioNational Cancer Data BaseMultivariate logistic regression analysisTreatment of patientsLogistic regression analysisRadical prostatectomyPrimary therapyCurative therapyPrimary outcomeCancer communityTherapySignificant racial disparitiesAcademic hospitalPatientsBlack menCancerHospitalStudy periodWhite menGenomic predictors of biochemical failure following radical prostatectomy.
Aneja S, Yu J, Glazer P. Genomic predictors of biochemical failure following radical prostatectomy. Journal Of Clinical Oncology 2016, 34: 114-114. DOI: 10.1200/jco.2016.34.2_suppl.114.Peer-Reviewed Original ResearchPathologic T stageGleason 7 diseaseBiochemical failureRadical prostatectomyT stageProstate adenocarcinomaClinical dataPredictors of BFAggressive regional therapyClinical patient characteristicsPre-treatment PSARNA expressionStratification of patientsHierarchical logistic regression modelsLogistic regression modelsMedian followAggressive therapyPatient characteristicsCancer Genome AtlasExpression of TP53Gleason 7Median ageRegional therapyGleason scoreClinical correlates
2015
MP56-06 ASSOCIATION BETWEEN PROVIDER-LEVEL FACTORS AND LYMPH NODE DISSECTION OUTCOMES DURING RADICAL PROSTATECTOMY: A NATIONAL CANCER DATABASE ANALYSIS
Kiechle J, Wang E, Yu J, Gross C, Abouassaly R, Cherullo E, Smaldone M, Shah N, Trinh Q, Sun M, Kim S. MP56-06 ASSOCIATION BETWEEN PROVIDER-LEVEL FACTORS AND LYMPH NODE DISSECTION OUTCOMES DURING RADICAL PROSTATECTOMY: A NATIONAL CANCER DATABASE ANALYSIS. Journal Of Urology 2015, 193: e683. DOI: 10.1016/j.juro.2015.02.2070.Peer-Reviewed Original ResearchAssociation between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.
Kiechle J, Wang E, Yu J, Gross C, Abouassaly R, Cherullo E, Smaldone M, Shah N, Trinh Q, Sun M, Kim S. Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis. Journal Of Clinical Oncology 2015, 33: 89-89. DOI: 10.1200/jco.2015.33.7_suppl.89.Peer-Reviewed Original ResearchPelvic lymph node dissectionHigh-risk prostate cancerLymph node countRobotic-assisted radical prostatectomyOpen radical prostatectomyRadical prostatectomyProstate cancerLymph nodesSurgical approachHospital characteristicsCommunity hospitalNode countNational Cancer Database AnalysisTime of RPUnderwent radical prostatectomyLymph node dissectionNational Cancer DatabaseLow-volume hospitalsProvider-level factorsPopulation-based cohortAggressive prostate cancerNode dissectionVolume hospitalsPrimary outcomeMultivariable analysis
2010
Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort
Schreiber D, Rineer J, Yu J, Olsheski M, Nwokedi E, Schwartz D, Choi K, Rotman M. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 2010, 116: 5757-5766. PMID: 20737571, DOI: 10.1002/cncr.25561.Peer-Reviewed Original ResearchConceptsProstate-specific antigenClinically localized prostate cancerPositive surgical marginsLocalized prostate cancerAdjuvant radiationRadical prostatectomySurgical marginsProstate cancerPathologic extentRate of organ-confined diseaseProstate-specific antigen levelRisk of extraprostatic extensionPatterns of care studyOrgan-confined diseaseNegative surgical marginsEnd Results databaseLogistic regression analysisPopulation-based studyExtraprostatic diseaseExtraprostatic extensionGleason 7Gleason 8Postoperative radiationProstatic adenocarcinomaResults databaseAdjuvant radiotherapy after radical prostatectomy: Evidence and analysis
Raldow A, Hamstra D, Kim S, Yu J. Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. Cancer Treatment Reviews 2010, 37: 89-96. PMID: 20667660, DOI: 10.1016/j.ctrv.2010.07.001.Peer-Reviewed Original ResearchConceptsTarget volumeIncreased risk of cancer recurrencePositive surgical marginsSeminal vesicle invasionTreatment target volumeLocalized prostate cancerRisk of cancer recurrenceSigns of recurrenceTreatment of patientsTechnical aspects of treatmentDecrease side effectsRandomized clinical trialsUndetectable PSAAdjuvant radiotherapyAdjuvant settingDose escalationExtracapsular extensionRadical prostatectomySurgical marginsRadiation therapyProstate cancerPathological examinationClinical outcomesCure rateCancer recurrenceSalvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy.
Raldow A, Hamstra D, Kim S, Yu J. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology 2010, 24: 692-700, 702. PMID: 20718248.Peer-Reviewed Original ResearchConceptsSalvage radiation therapyAdjuvant radiation therapyRadical prostatectomyProstate cancerRadiation therapyPost-operative adjuvant radiation therapyBiochemical recurrence of prostate cancerImmediate adjuvant radiation therapySalvage external beam radiotherapyEvidence of recurrent diseaseRecurrence of prostate cancerExternal beam radiotherapyCause of cancer deathRadiotherapy volumeBeam radiotherapyBiochemical recurrenceRecurrent diseaseRandomized trialsCancer deathProstatectomySide effectsProstatePatientsCancerRadiotherapy